<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03629132</url>
  </required_header>
  <id_info>
    <org_study_id>RPR-IUAs</org_study_id>
    <nct_id>NCT03629132</nct_id>
  </id_info>
  <brief_title>PRP Prevents Recurrence of Intrauterine Adhesions</brief_title>
  <acronym>RPR-IUAs</acronym>
  <official_title>Platelet-rich Plasma(PRP) Prevents Recurrence of Intrauterine Adhesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yanhong Deng</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of platelet-rich plasma (PRP) on uterine scar fibrosis, endometrial receptivity and
      pregnancy outcome in patients with severe intrauterine adhesions
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Inclusion criteria: patients with intrauterine adhesions (AFS score &gt;9 points); age 21
           to 40 years old, with fertility requirements.

        2. Study design:prospective, randomized controlled cohort study, patients with intrauterine
           adhesions were randomized into two groups, the control group and the intervention group
           (intraoperative and postoperative 1 week postoperative PRP). The surgical procedures and
           postoperative medication regimens were the same.

        3. Compare the biochemical pregnancy rate, clinical pregnancy rate, abortion rate and live
           birth rate after hysteroscopic resection in PRP group and control group, and explore the
           effect of PRP on pregnancy outcome after intrauterine adhesion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AFS score</measure>
    <time_frame>1 year</time_frame>
    <description>AFS score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intrauterine Adhesion</condition>
  <arm_group>
    <arm_group_label>PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelet-rich plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gel</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Self-crosslinking sodium hyaluronate gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Platelet-rich plasma</intervention_name>
    <description>Platelet-rich plasma intrauterine injection</description>
    <arm_group_label>PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>gel</intervention_name>
    <description>Self-crosslinking sodium hyaluronate gel intrauterine injection</description>
    <arm_group_label>Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients with intrauterine adhesions (AFS score &gt;9 points); age 21 to 40
        years old, with fertility requirements -

        Exclusion Criteria:Endometrial tuberculosis, endometrial polyps, uterine submucosal
        fibroids, endometrial hyperplasia, endometrial malignant lesions, premature ovarian
        failure, chromosomal abnormalities

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>37 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 9, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2018</study_first_posted>
  <last_update_submitted>August 9, 2018</last_update_submitted>
  <last_update_submitted_qc>August 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yanhong Deng</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Tissue Adhesions</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

